middle.news
How Immutep’s IMP761 Silences T Cells to Tackle Autoimmune Diseases
8:44am on Monday 23rd of June, 2025 AEST
•
Biotechnology
Read Story
How Immutep’s IMP761 Silences T Cells to Tackle Autoimmune Diseases
8:44am on Monday 23rd of June, 2025 AEST
Key Points
IMP761 achieves 80% T cell suppression at 0.9 mg/kg dose
No treatment-related adverse events observed in healthy volunteers
Phase I dose escalation continues with higher doses planned
Targeting major autoimmune diseases including rheumatoid arthritis and type 1 diabetes
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE